Implementation of Tax Cuts and Jobs Act. International tax proposals related to intellectual property.
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. Issues pertaining to drug costs. Issues related to H.R. 1628, the American Health Care Act
FY 2019 appropriations
Duration: November 1, 2007
to
December 31, 2018
General Issues: Taxation/Internal Revenue Code , Health Issues , Budget/Appropriations , Government Issues , Medicare/Medicaid , Pharmacy
Spending: about $1,619,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: House of Representatives, U.S. Senate, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Brian Sutter Staff Dir., W&M Health Subcommittee, Chairman Dave Camp April, 2013 - Dec. 2014; Professional Staff, W&M Health Subcommittee, Chairman Dave Camp, Jan. 2011 - April 2013;Leg Dir., Rep. Dave Camp, May '08 - Jan.,'11
Leg Asst.Rep Camp, Feb '03-May'08;
Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02
Tom Wharton Health Legislative Assistant - Senator Joe Lieberman. May 2011 - June 2012
Senior Legislative Assistant - Congressman Dan Boren. July 2008 - June 2011
Chris Bowlin Health Policy Advisor for Senator McCain 2009-Aug. 2013; Dep
Amy Shank 2005-2011 Senate HELP Cmte; Dir. of Oversight
2003-2004 Senate Budget Committee
2001-2002 Ofc. of GOP Leader Don Nickles
2001-2002 Ofc. of Asst. GOP Leader Don Nickles
2005-2011 Senate HELP Cmte, Dir. of Oversight
2003-2004 Budget Committee
Surya Gunasekara Chief of Staff and Tax Counsel - Rep. James B. Renacci May 2015 - Aug. 2017.
David Stratton Edwards Staff Assistant for Rep. John Sullivan Nov. 2003 - Aug. 2006. Legislative Counsel for Rep. Tom Cole Aug. 2010 - Mar. 2015
David Stratton Edward Staff Assistant for Rep. John Sullivan Nov. 2003 - Aug. 2006. Legislative Counsel for Rep. Tom Cole Aug. 2010 - Mar. 2015
David Jory n/a
Bill K. Brewster n/a
Steve Irizarry n/a
William Duncan n/a
Brian Munroe n/a
Robbie Koch Sabathier n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2018
CAPITOL HILL CONSULTING GROUP terminated an engagement in which they represented NOVARTIS CORPORATION on Jan. 20, 2019.
Original Filing: 301011067.xml
Lobbying Issues
Implementation of Tax Cuts and Jobs Act. International tax proposals related to intellectual property.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. Issues pertaining to drug costs. Issues related to H.R. 1628, the American Health Care Act
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $50,000. The report was filed on Oct. 11, 2018.
Original Filing: 300984266.xml
Lobbying Issues
Implementation of Tax Reform, international tax proposals related to intellectual property.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. Issues pertaining to drug costs. Issues related to H.R. 1628, the American Health Care Act
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $50,000. The report was filed on July 20, 2018.
Original Filing: 300977089.xml
Lobbying Issues
Implementation of Tax Reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. Issues pertaining to drug costs. Issues related to H.R. 1628, the American Health Care Act
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on April 20, 2018.
Original Filing: 300954853.xml
Lobbying Issues
General Corporate Tax Reform; International corporate taxation under HR 1 (115. Tax Cuts and Jobs Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. Issues pertaining to drug costs. Issues related to H.R. 1628, the American Health Care Act
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934793.xml
Lobbying Issues
General Corporate Tax Reform; International corporate taxation;
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. Issues pertaining to drug costs. Issues related to H.R. 1628, the American Health Care Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on Oct. 19, 2017.
Original Filing: 300909927.xml
Lobbying Issues
General Corporate Tax Reform; International corporate taxation;
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. Issues pertaining to drug costs. Issues related to H.R. 1628, the American Health Care Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on July 20, 2017.
Original Filing: 300895508.xml
Lobbying Issues
General Corporate Tax Reform; International corporate taxation;
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. Issues pertaining to drug costs. Issues related to H.R. 1628, the American Health Care Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on April 20, 2017.
Original Filing: 300877011.xml
Lobbying Issues
General Corporate Tax Reform; International corporate taxation;
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. Issues pertaining to drug costs. Issues related to H.R. 1628, the American Health Care Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on Jan. 20, 2017.
Original Filing: 300852960.xml
Lobbying Issues
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension; International corporate taxation; Inversion regulations and legislation
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. H.R. 5182, the Promoting Life-Saving New Therapies for Neonates Act of 2016
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on Oct. 20, 2016.
Original Filing: 300837717.xml
Lobbying Issues
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension; International corporate taxation; Inversion regulations and legislation
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. H.R. 5182, the Promoting Life-Saving New Therapies for Neonates Act of 2016
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on July 20, 2016.
Original Filing: 300819492.xml
Lobbying Issues
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension; International corporate taxation; Inversion regulations and legislation
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. H.R. 5182, the Promoting Life-Saving New Therapies for Neonates Act of 2016
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on April 15, 2016.
Original Filing: 300791775.xml
Lobbying Issues
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension; International corporate taxation; Inversion regulations and legislation
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $20,000. The report was filed on Jan. 20, 2016.
Original Filing: 300781437.xml
Lobbying Issues
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $20,000. The report was filed on Oct. 20, 2015.
Original Filing: 300762589.xml
Lobbying Issues
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $20,000. The report was filed on July 15, 2015.
Original Filing: 300735208.xml
Lobbying Issues
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $20,000. The report was filed on April 16, 2015.
Original Filing: 300717631.xml
Lobbying Issues
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Biosimilar Approvals
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $20,000. The report was filed on Jan. 16, 2015.
Original Filing: 300699140.xml
Lobbying Issues
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $20,000. The report was filed on Oct. 16, 2014.
Original Filing: 300678707.xml
Lobbying Issues
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $20,000. The report was filed on July 8, 2014.
Original Filing: 300654267.xml
Lobbying Issues
General corporate tax reform; Orphan Drug Credit; Research and experimentation tax credit extension
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $18,000. The report was filed on April 16, 2014.
Original Filing: 300637289.xml
Lobbying Issues
General corporate tax reform; Orphan Drug Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2013
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $18,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616688.xml
Lobbying Issues
General corporate tax reform; Orphan Drug Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2013
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $18,000. The report was filed on Oct. 9, 2013.
Original Filing: 300591956.xml
Lobbying Issues
General corporate tax reform; Orphan Drug Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $22,000. The report was filed on July 10, 2013.
Original Filing: 300570235.xml
Lobbying Issues
General corporate tax reform; Orphan Drug Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of NOVARTIS CORPORATION in Q12013 on April 17, 2013.
Original Filing: 300552453.xml
Lobbying Issues
General corporate tax reform; Orphan Drug Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $18,000. The report was filed on April 17, 2013.
Original Filing: 300552301.xml
Lobbying Issues
General corporate tax reform; Orphan Drug Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2012
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on Jan. 16, 2013.
Original Filing: 300530203.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Prescription and Generic Drug User Fees legislation; Public Health Service Act (42 USC 6A); Biosimilars; Patient Protection and Affordable Care Act (P.L. 111-148)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General patent issues; America Invents Act (S. 23)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General FDA funding issues; FY 2014 Labor-HHS-Education Appropriations; Pandemic vaccine issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2012
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on Oct. 10, 2012.
Original Filing: 300504992.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Prescription and Generic Drug User Fees legislation; Public Health Service Act (42 USC 6A); Biosimilars; Patient Protection and Affordable Care Act (P.L. 111-148)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General patent issues; America Invents Act (S. 23)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General FDA funding issues; FY 2013 Labor-HHS-Education Appropriations; Pandemic vaccine issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2012
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on July 12, 2012.
Original Filing: 300483149.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Prescription and Generic Drug User Fees legislation; Public Health Service Act (42 USC 6A); Biosimilars; Patient Protection and Affordable Care Act (P.L. 111-148)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General patent issues; America Invents Act (S. 23)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General FDA funding issues; FY2012 Labor-HHS-Education Appropriations; Pandemic vaccine issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2012
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $30,000. The report was filed on April 11, 2012.
Original Filing: 300459217.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Biosimilars; Patient Protection and Affordable Care Act (P.L. 111-148)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General patent issues; America Invents Act (S. 23)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General FDA funding issues; FY2012 Labor-HHS-Education Appropriations; Pandemic vaccine issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2011
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $65,000. The report was filed on Jan. 17, 2012.
Original Filing: 300438809.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Biosimilars; Patient Protection and Affordable Care Act (P.L. 111-148)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General patent issues; America Invents Act (S. 23)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General FDA funding issues; FY2012 Labor-HHS-Education Appropriations; Pandemic vaccine issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2011
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $80,000. The report was filed on Oct. 13, 2011.
Original Filing: 300413101.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Biosimilars; Patient Protection and Affordable Care Act (P.L. 111-148)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General patent issues; America Invents Act (S. 23)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General FDA funding issues; FY2012 Labor-HHS-Education Appropriations; Pandemic vaccine issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2011
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $80,000. The report was filed on July 19, 2011.
Original Filing: 300394715.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Biosimilars; Patient Protection and Affordable Care Act (P.L. 111-148)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General patent issues; America Invents Act (S. 23)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General FDA funding issues; FY2012 Labor-HHS-Education Appropriations; Pandemic vaccine issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2011
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $80,000. The report was filed on April 19, 2011.
Original Filing: 300370205.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Biosimilars; Patient Protection and Affordable Care Act (P.L. 111-148)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General patent issues; America Invents Act (S. 23)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General FDA funding issues; FY2012 Labor-HHS-Education Appropriations; Pandemic vaccine issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2010
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $80,000. The report was filed on Jan. 20, 2011.
Original Filing: 300348287.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; Preserve Access to Affordable Generics Act (S. 369)
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General FDA funding issues; FY2011 Labor-HHS-Education Appropriations; FY2011 Supplemental Appropriations; Pandemic vaccine issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2010
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of NOVARTIS CORPORATION in Q32010 on Oct. 18, 2010.
Original Filing: 300315737.xml
Lobbying Issues
General health care issues related to pharmeuceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA funding issues, generally; FY 2010 Labor-HHS-Labor Appropriations; FY2010 Supplemental Appropriations; Pandemic vaccine issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S. 301)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $40,000. The report was filed on Oct. 14, 2010.
Original Filing: 300313195.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA funding issues, generally; FY2010 Labor-HHS-Labor Appropriations; FY2010 Supplemental Appropriations; Pandemic vaccine issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S. 301)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $40,000. The report was filed on July 14, 2010.
Original Filing: 300286840.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA funding issues, generally, FY2010 Labor-HHS Appropriations; FY2010 Supplemental Appropriations; Pandemic vaccine issues;
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S.301)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $40,000. The report was filed on April 19, 2010.
Original Filing: 300266872.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA funding issues, generally, FY2010 Labor-HHS Appropriations; FY2010 Supplemental Appropriations;; Pandemic vaccine issues; American Recovery and Reinvestment Act (H.R. 1)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S.301)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $40,000. The report was filed on Jan. 14, 2010.
Original Filing: 300231105.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices Act (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA funding issues, generally, FY2010 Labor-HHS Appropriations; FY2010 Supplemental Appropriations;; Pandemic vaccine issues; American Recovery and Reinvestment Act (H.R. 1)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S.301)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $40,000. The report was filed on Oct. 6, 2009.
Original Filing: 300201085.xml
Lobbying Issues
general healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Promoting Innovation and Access to Lifesaving Medicine Act (HR1427/S.726); Pathway for Biosimilars Act (HR1548); Biologics Price Competition and Innovation Act of 2007; drug safety; follow-on biologics; America's Affordable Health Choices Act (HR3200); America's Healthy Future Act
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA funding issues, generally, FY2010 Labor-HHS Appropriations; FY2010 Supplemental Appropriations; Pandemic vaccine issues; American Recovery and Reinvestment Act (HR1)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Meidcare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician gifts; Physician Payments Sunshine Act (S.301)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $40,000. The report was filed on July 14, 2009.
Original Filing: 300176972.xml
Lobbying Issues
general healthcare issues related to pharmaceutical and biological products; Federal Food, Drug, and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); FDA Globalization Act (HR759); Promoting Innovation and Access to Lifesaving Medicine Act (HE1427/S.726); Pathway for Biosimilars Act (HR1548); Biologics Price Competition and Innovation Ace of 2007; drug safety; follow-on biologics
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA funding issues, generally, FY2010 Labor-HHS Appropriations; FY2010 Supplemental Appropriations; Pandemic vaccine issues; American Recovery and Reinvestment Act (HR1)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; Physician gifts; Physician Payments Sunshine Act (S.301)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $40,000. The report was filed on April 14, 2009.
Original Filing: 300147976.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); drug safety; Food and Drug Administration Amendments Act of 2007 (Public Law No:110-85); FDA Globalization Act (HR 759); Follow-on biologics: American Recovery and Reinvestment Act of 2009 (Public Law No. 111-5)
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA funding issues, generally, FY2009 Labor-HHS Appropriations; FY 2009 Department of Defense Appropriations; FY 2009 Supplemental Appropriations. Vaccines: Funding for the Transformational Medical Technologies Initiative (TMTI)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician gifts; Physician Payments Sunshine Ace (S. 2029); Drug and Medical Device Company Gift Disclosure Act (HR 3023); False Claims Act Correction Act (HR 4854/S. 2041)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $40,000. The report was filed on Jan. 15, 2009.
Original Filing: 300119332.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9);
Public Health Service Act (42 USC 6A); Drug safety: Food and Drug Administration Amendments Act of 2007 (Public Law No: 110-85); Food and Drug Import Safety Act (HR 3610); Drug reimportation: Pharmaceutical Market Access Act (S. 251); Pharmaceutical Market Access and Drug Safety Act (S. 242/HR 380).Follow-on biologics: Access to Life-Saving Medicine Act (HR 1038); Patient Protection and Innovative Biologic Medicines Act (HR 1956); Biologics Price Competition and Innovation Act (S. 1695); Pathway for Biosimilars Act (HR 5629).
Comparative Effectiveness: Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (HR 2184).
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA funding issues, generally. FY2009 Labor-HHS Appropriations; FY2009 Department of Defense Appropriations; FY2009 Supplemental Appropriations. Vaccines: Funding for the Transformational Medical Technologies Initiative (TMTI)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician gifts: Physician Payments Sunshine Act (S. 2029); Drug and Medical Device Company Gift Disclosure Act (HR 3023); False Claims Act Correction Act (HR 4854/S. 2041); Medicare Part D: Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173); Medicare Prescription Price Negotiation Act (HR 4/S. 3).Medicare Improvements for Patients and Providers Act (HR 6331); Supplemental Appropriations Act (HR 2642).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $40,000. The report was filed on Oct. 17, 2008.
Original Filing: 300097019.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9);
Public Health Service Act (42 USC 6A); Drug safety: Food and Drug Administration Amendments Act of 2007 (Public Law No: 110-85); Food and Drug Import Safety Act (HR 3610); Drug reimportation: Pharmaceutical Market Access Act (S. 251);
Pharmaceutical Market Access and Drug Safety Act (S. 242/HR 380).
Follow-on biologics: Access to Life-Saving Medicine Act (HR 1038); Patient Protection and Innovative Biologic Medicines Act (HR 1956); Biologics Price Competition and Innovation Act (S. 1695); Pathway for Biosimilars Act (HR 5629).
Comparative Effectiveness: Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (HR 2184).
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA funding issues, generally.
FY2009 Labor-HHS Appropriations; FY2009 Department of Defense Appropriations; FY2009 Supplemental Appropriations.
Vaccines: Funding for the Transformational Medical Technologies Initiative (TMTI)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician gifts: Physician Payments Sunshine Act (S. 2029); Drug and Medical Device Company Gift Disclosure Act (HR 3023); False Claims Act Correction Act (HR 4854/S. 2041); Medicare Part D: Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173); Medicare Prescription Price Negotiation Act (HR 4/S. 3).Medicare Improvements for Patients and Providers Act (HR 6331); Supplemental Appropriations Act (HR 2642).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $50,000. The report was filed on July 9, 2008.
Original Filing: 300062575.xml
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
General Healthcare issues related to vaccine and prescription drug legislation; comparative effectiveness research; Public Health Service Act; Drug Importation; (S.1505) Affordable Biologics for Consumers Act; (S.1695) Biologics Price Competition and Innovation Act; (H.R. 1956) Patient Protection and Innovative Biologic Medicines Act; (H.R.1038) Access to Life-Saving Medicine Act; (S.623) Access to Life Saving Medicine Act; direct to consumer advertising; FDA funding; Reagan/Udall Foundation
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Pharmaceutical and Life Sciences issues, including but not limited to: The Federal Food, Drug and Cosmetic Act; The Hatch-Waxman Act; drug safety
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
DoD Authorization Language- Section 701, Dealing with TriCare; FY2009 Labor HHS Appropriations Bill; FY2009 Department of Defense Appropriations Bill; 2009 Supplemental Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
(S.2029) Physician Payments Sunshine Act; Access to Life Saving Medicines Act; Medicare Part D-Non-Interference; Medicare Prescription Drugs and Modernization Act; (H.R.3023) Drug and Medical Device Company Gift Disclosure Act; (S.2041) False Claims Act Correction Act; (H.R.4854) False Claims Act Correction Act; (H.R.3610) Food and Drug Import Safety Act
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $50,000. The report was filed on April 16, 2008.
Original Filing: 300038716.xml
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
General healthcare issues related to vaccine and prescription drug legislation; comparative effectiveness research; Public Health Service Act; drug importation; (S.1505) Affordable Biologics for Consumers Act; (S.1695) Biologics Price Competition and Innovation Act; (H.R. 1956) Patient Protection and Innovative Biologic Medicines Act; (H.R. 1038) Access to Life-Saving Medicine Act; (S.623) Access to Life Saving Medicine Act; direct to consumer advertising; FDA funding; Reagan/Udall Foundat
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Pharmaceutical and life sciences issues, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatch-Waxman Act; drug safety
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
DoD Authorization Language- Section 701, Dealing with TriCare; FY2009 Labor HHS Appropriations Bill; FY2009 Department of Defence Appropriations Bill; 2009 Supplemental Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
(S. 2029) Physician Payments Sunshine Act; Access to Life Saving Medicines Act; Medicare Part D-Non-Interference; Medicare Prescription Drugs and Modernization Act; (H.R. 3023) Drug and Medical Device Company Gift Disclosure Act; (S. 2041) False Claims Act Correction Act; (HR 4854) False Claims Act Correction Act;( HR 3610) Food and Drug Import Safety Act
Agencies Lobbied
U.S. House of Representatives
0th Quarter, 2007
In MM, CAPITOL HILL CONSULTING GROUP lobbied for NOVARTIS CORPORATION , earning $40,000. The report was filed on Aug. 1, 2007.
Original Filing: 200043641.xml
Lobbying Issues
General healthcare issues related to vaccine and prescription drug legislation
Type of Issue
Taxation/Internal Revenue Code
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...